Options expected to have increasing volume: CHGG EA MGI GILD TAP NVDA KO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Gilead Sciences (GILD) PT Lowered to $87 at Cantor Fitzgerald
February 12, 2019 7:14 AM ESTCantor Fitzgerald analyst Alethia Young lowered the price target on Gilead Sciences (NASDAQ: GILD) to $87.00 (from $92.00) while maintaining a Overweight rating after speaking with management.
STELLAR3 is set to read out in 2Q, and Cantor Fitzgerald has increased caution after the F4... More
Gilead Sciences (GILD) NASH Expectations Were Low, RBC Says; PT Trimmed to $84
February 12, 2019 6:53 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on Gilead Sciences (NASDAQ: GILD) to $84.00 (from $89.00) while maintaining a Outperform rating after the company announced its first ph.III study of selonsertib in NASH, STELLAR 4, failed.
"... we believe expectations were low... More
